$IX Biopharma(42C.SI)$ $0.8 Target Price

--About IX Biopharma (42C.SI)--

iX Biopharma Ltd (SGX: 42C) is a specialty pharmaceutical and nutraceutical company focused on developing, manufacturing, and commercializing products using its proprietary sublingual drug delivery technologies. Its core growth catalysts center on commercial technology expansion, U.S. market entry, and joint venture/licensing opportunities.

--Growth Catalysts for iX Biopharma--

1). Commercialization & Out-Licensing of WaferiX®: Monetization of its patented sublingual wafer platform (WaferiX®, WaferlogiX) via out-licensing deals, tech transfers, and manufacturing agreements for repurposed pharmaceutical molecules (such as Wafermine for pain management and Wafesil for ED).

2). U.S. Market & Compounding Pharmacy Expansion: Execution of a capital-light U.S. strategy distributing products via compounding pharmacies and strategic partners to target the fast-growing anti-aging, longevity, and wellness markets.

3). Growth in Medicinal Cannabis Operations: Expansion of specialty pharmaceutical offerings, particularly through supplying sublingual medicinal cannabis formulations and manufacturing services to the Australian market.

4). Nutraceutical Division Expansion: Scaling up global direct-to-consumer (DTC) and e-commerce sales for key sublingual health supplements like SL-NAD+ and LumeniX across major target regions including China, Australia, and North America.

5). Strategic Joint Ventures & Partnerships: Potential partnerships, consumer business restructurings, and JV collaborations (such as with GLD Partners / Orion Specialty Labs) to scale product distribution, lower operating cash burn, and accelerate path to profitability.

6). Major Shareholder Support include:

Yip Hang Lee (Chairman/CEO) — 22.9% stake, recently increased by ~9.6M shares

CIMB-GK Securities — 10.9%

Lion Global Investors — 4.89% (new addition of ~30.8M shares, indicating institutional interest)

Insider buying and institutional entry are strong positive signals, for exponential growth. 

7). Diversified client base

IX Biopharma is a Singapore-listed specialty pharmaceutical company focused on developing and commercialising innovative drug delivery systems. Its revenue is geographically diversified, with Australia (48.1%) and the United States (36.7%) as the two largest markets, followed by Singapore & Others (8.0%) and China (7.2%) based on the latest 2026Q1 data.